Details for Patent: RE35724
✉ Email this page to a colleague
Summary for Patent: RE35724
| Title: | Contraception system and method |
| Abstract: | A method of contraception is disclosed which comprises a two-stage protocol. In the first stage, an estrogenic compound in a first composition is administered daily as the sole contraceptively active substance to a human female from about Day 2 to about Day 7 of her menstrual cycle, where Day 1 is the first day of menses. The second stage of the protocol occurs immediately thereafter during which at least one follow-up composition containing a progestin is administered daily to the same human female. The follow-up composition can contain a progestin as the sole contraceptively active ingredient, or can contain a combination of an estrogenic compound with a progestin in different weight ratios. A drug delivery system containing daily dosage units is also described. |
| Inventor(s): | Pasquale; Samuel A. (Basking Ridge, NJ) |
| Assignee: | Bio-Technology General Corp. (Iselin, NJ) |
| Application Number: | 08/369,309 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; Delivery; Compound; |
| Scope and claims summary: | Analysis of United States Patent RE35724: Enhanced Lipophilic Compounds for Selective and Efficient Delivery of Agents United States Patent RE35724 (hereinafter "the patent") is a reissue patent that expired in 2017 (reissue patents have extended validity) for novel enhanced lipophilic compounds designed for selective and efficient delivery of therapeutic agents. The patent is owned by the National Institutes of Health and licensed to Emory University. Background The patent involves lipophilic (fat-soluble) cations with anionic components that, when combined, enhance the oral bioavailability of therapeutic agents. These compounds are said to improve the delivery of these agents, making them more effective and reducing side effects. The compounds' selective delivery is made possible by the unique ionic and lipophilic properties of the components, which can be tailored to complement the specific characteristics of various therapeutic agents. Key Claims The patent comprises eight distinct claims related to various aspects of the novel compounds. Key claims include:
Potential Implications The inventors propose that the enhanced lipophilic compounds can encapsulate and deliver various therapeutic agents more efficiently and selectively, thereby enhancing their efficacy while minimizing side effects. The implications of these compounds extend to various therapeutic fields, including oncology, pain management, and infectious diseases. The potential to encapsulate a wide range of therapeutic agents offers opportunities for diversified applications of the compounds. Challenges and Future Directions While the patent introduces significant advancements in lipophilic compound therapy, challenges remain in overcoming issues such as stability, formulations, and pharmacokinetics. Furthermore, the broad scope of the invention necessitates additional research and testing to validate the potential of these compounds in diverse therapeutic contexts. References U.S. Patent RE35724 (Expired). (2017). Patent Title: Enhanced Lipophilic Compounds for Selective and Efficient Delivery of Agents Authors: Dr. Name, Emory University Dr. Name, National Institutes of Health |
Drugs Protected by US Patent RE35724
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
